64 results about "Tissue inflammation" patented technology

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The invention discloses a histone-derived peptide nano-particle for targeted degradation of cytoplasm cGAS and a preparation method and application thereof, and is characterized in that a polypeptide compound is dissolved in a phosphate buffer, ultrasonic treatment and room temperature standing self-assembly are performed to form nano-particles, and centrifugal purification is performed to obtain the histone-derived peptide nano-particle A4-CMA NPs for targeted degradation of cytoplasm cGAS. The nano-particles (A4 at CMA NPs) can be combined with cytoplasm cGAS in a targeted manner and mediate the cytoplasm cGAS to degrade, so that the activation of a cGAS-STING pathway is blocked, periodontal tissue inflammation and alveolar bone resorption are effectively relieved, and a new strategy is provided for periodontitis treatment.

The application relates to the field of high polymer materials, in particular to an exosome composite material for treating periodontitis and a preparation method thereof. The exosome composite material comprises the following raw materials in parts by weight: 10-20 parts of a chitosan derivative, 10-20 parts of sodium hyaluronate, 1-5 parts of zein, 0.5-1 part of exosomes, 0.1-0.3 parts of phosphonodipeptide sodium and 60-70 parts of deionized water. The exosome composite material can inhibit periodontal pathogenic bacteria, reduce the expression of proinflammatory factors by inhibiting the signal pathways such as NF-kappa B, and thus relieve periodontal tissue inflammation.

The invention discloses a periodontitis marker and application thereof. Belongs to the technical field of biomedical detection. Experiments prove that the expression of the hsacirc0005737 in patient tissues, periodontal ligament stem cells in an inflammation microenvironment and periodontitis model mouse tissues is remarkably up-regulated, and the expression level of the hsacirc0005737 is positively correlated with the severity and activity of periodontitis. Therefore, detection of the expression level can be used for diagnosis, activity evaluation, curative effect monitoring and prognosis of periodontitis. In addition, the osteogenic differentiation capacity and inflammatory response of the periodontal ligament stem cells can be influenced by regulating the expression of the hsacirc0005737, so that the hsacirc0005737 can be used as a potential target for treating periodontitis. The invention further provides a primer sequence, a detection reagent combination and a kit for detecting the hsacirc0005737, and a new solution is provided for noninvasive, early-stage and high-specificity diagnosis and targeted therapy of periodontitis.

This invention discloses a histone-derived peptide nanoparticle targeting the degradation of cytoplasmic cGAS, its preparation method, and its applications. The invention is characterized by: dissolving a peptide complex in phosphate buffer, sonicating, allowing it to self-assemble at room temperature to form nanoparticles, and purifying by centrifugation to obtain histone-derived peptide nanoparticles A4@CMA NPs targeting the degradation of cytoplasmic cGAS. These nanoparticles (A4@CMA NPs) can target and bind to cytoplasmic cGAS, mediating its degradation, blocking the activation of the cGAS-STING pathway, effectively reducing periodontal inflammation and alveolar bone resorption, and providing a new strategy for the treatment of periodontitis.

Disclosed are methods, systems, media, apparatus, devices, and other implementations, including a method that includes determining blood flow characteristics at an ocular surface of an eye of a patient, determining characteristics of blood vessels at the ocular surface of the eye based on the determined blood flow characteristics, and deriving one or more ocular redness grading scales indicative of inflammation levels of the eye of the patient based on the determined characteristics of the blood vessels at the ocular surface of the eye.

The present application relates to the technical field of medical devices, and particularly relates to a controlled release device, a preparation method thereof and an intelligent microneedle closed loop system. The controlled release device comprises a metal microneedle, a doped polypyrrole film coated on the surface of the metal microneedle and a drug loaded on the doped polypyrrole film. The controlled release device realizes the electrically controlled on-demand release of hypoglycemic drugs, and can make metformin release 41.1 mu g in 400 minutes, thereby providing a new possibility for personalized treatment of diabetes. Meanwhile, the present application also constructs an intelligent microneedle closed loop system by using a microneedle sensor, realizes real-time monitoring of blood glucose and linkage control of on-demand drug delivery, and can be continuously worn for seven days without tissue inflammation.

The main purpose set by the present inventors is to provide a technology for suppressing inflammation particularly in aged tissue in the oral cavity.　The present inventors have discovered that it is possible to suppress inflammation particularly in aged tissue in the oral cavity by an oral cavity composition that contains β-glycyrrhetinic acid and at least one selected from the group consisting of retinol acetate, retinol, all-trans-retinoic acid, ascorbic acid, cobalamin, calciferol, anthraquinone, L-histidine, methylhesperidin, and chemically possible salts thereof.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.

The invention provides a construction method and application of a chicken fallopian tube embolism model, and belongs to the technical field of animal infection models. The invention provides a construction method of a chicken fallopian tube embolism model based on multi-pathogen infection. The mycoplasma synoviae, the infectious bronchitis virus and the riemerella anatipestifer are utilized to infect the chicken, and the clinical typical salpingemphasis pathological process including cheese-like substance accumulation in a salpingemphasis cavity, serious abdominal air sacculitis complications and related tissue inflammation changes can be accurately reproduced. The model constructed by the invention is high in morbidity, and is suitable for epidemic disease pathogenesis research, drug screening and vaccine potency test. Compared with an existing single pathogen infection model, the model is closer to a clinical reality multi-pathogen cooperative infection scene, and the blank of a standardized multi-pathogen mixed infection induced fallopian tube embolism animal model is filled up.

The invention relates to the technical field of biological medicine, in particular to an efficient macrophage targeting vesicle system as well as a preparation method and application thereof. The vesicle system is a chimeric vesicle (mHEs), and is prepared from extracellular vesicles (M2-EVs) derived from M2 type macrophages and apoptotic small bodies (MSC-ABs) derived from bone marrow mesenchymal stem cells. The vesicle system provided by the invention can realize specific recognition and functional regulation of macrophages, thereby playing an efficient therapeutic role in pathological processes such as tissue inflammation repair, myocardial infarction, ischemia-reperfusion injury and immune metabolism remodeling.

The invention discloses an application of OTX008 in the treatment of HSV-1 virus infection. The application verifies that the galectin-1 selective inhibitor OTX008 can remarkably promote activation of an I-type interferon signal channel of a host after virus infection by constructing a mouse model infected by an HSV-1 virus; tissue inflammation damage caused by virus infection can be relieved; the immunopotentiator shows an immunopotentiation effect in mouse peritoneal macrophages. Therefore, the OTX008 disclosed by the invention can be used for promoting the function of an innate immune cell and inhibiting the replication of the HSV-1 virus in the cell; an immune escape strategy of the HSV-1 virus is cracked; the defect of high drug resistance of the traditional HSV-1 virus treatment drug is overcome to a certain extent; according to the application, a new host drug target spot is found, and a good clinical application prospect in resisting HSV-1 virus infection is shown.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to application of herba artemisiae scopariae and an ethanol herba artemisiae scopariae extract in a medicine for treating autoimmune hepatitis, the ethanol herba artemisiae scopariae extract can reduce ALT and AST of a patient suffering from the autoimmune hepatitis, can effectively reverse liver tissue lesions of the patient suffering from the autoimmune hepatitis, and has the advantages that the curative effect is good, and the curative effect is good. The content of collagen fibrinogen in animal livers is reduced, so that hepatic fibrosis of patients with the autoimmune hepatitis is effectively reversed, proinflammatory factors TNF-alpha, IL-6 and IL-1beta in serum are reduced, the content of an anti-inflammatory factor IL-10 is increased, and the composition has a protective effect on inflammatory injury of liver tissues with the autoimmune hepatitis and can be used for treating the liver with the autoimmune hepatitis. And the content of serum immune globulins IgG and IgM can also be reduced. Through the effects, the oriental wormwood and the ethanol oriental wormwood extract can effectively improve autoimmune hepatitis.

The present invention provides methods and materials for treating mammals (e.g., humans) that have or are at risk of developing a disease or condition characterized by tissue inflammation and / or degeneration. [Solution] For example, mesenchymal stem cells (MSCs) that express tissue-targeting antigen receptors (e.g., chimeric antigen receptors) capable of exerting immunosuppressive effects in targeted tissues are provided, as well as a method using such MSCs.

The invention discloses application of an iron chelating agent in treatment of HSV-1 and VSV virus infection. By constructing a mouse model infected by HSV-1 and VSV viruses, it is verified that the iron chelating agent can significantly promote activation of an I-type interferon signal channel of a host after virus infection; virus replication in various tissues can be inhibited, and secretion of antiviral cell factors can be promoted; tissue inflammation damage caused by virus infection can be relieved; the immunopotentiator shows a consistent immunopotentiation effect in mouse and human immune cells; the iron chelating agent is selected from any one or a combination of more of deferoxamine mesylate, deferiprone and ciclopirox. The iron chelating agent provided by the invention does not depend on virus TK / DNApol, overcomes the defect of high drug resistance of traditional HSV-1 and VSV virus treatment drugs to a certain extent, and has good clinical application prospects and application values.

1. The name of the design product: laser hair removal treatment head. 2. The use of the design product: laser through the hair removal treatment head on the skin, ease or eliminate the corresponding area of inflammation or discomfort of the organization. 3. The design points of the design product: in the front view. 4. The picture or photo that best indicates the design points: front view.

The invention relates to the technical field of biology, and discloses a Lactobacillus paracasei KFY202407 and an application thereof in preparation of a preparation for preventing and treating vaginitis, the collection number of the Lactobacillus paracasei KFY202407 in China General Microbiological Culture Collection Center (CGMCC) is CGMCC NO: 30736, and the collection date is May 22, 2024. The lactobacillus paracasei KFY202407 disclosed by the invention can relieve inflammation of mice with vaginitis by regulating secretion of mouse serum inflammatory factors, activity of vaginal tissue MPO and expression conditions of vaginal tissue inflammatory genes. The microbial inoculum prepared from the lactobacillus paracasei KFY202407 has good stability and can be used as a medicine raw material.

The invention discloses lactobacillus reuteri CCFM1502 capable of up-regulating skin ceramide synthesis and reducing skin inflammation and a metagen of the lactobacillus reuteri CCFM1502, and belongs to the technical field of microorganisms and medicines. The lactobacillus reuteri CCFM1502 provided by the invention can remarkably promote synthesis of ceramide when being externally used and orally taken, and can reduce skin inflammation response of mice after being orally taken. Specifically, the strain lysate and the fermentation supernatant both can promote HaCaT cells to secrete ceramide; the total amount of ceramide in skin can be up-regulated by oral administration of viable bacteria and metabiotics of the lactobacillus reuteri, apparent indexes of the skin can be regulated and controlled, inflammatory reactions in vivo and tissues can be reduced, and particularly, the effect of fermentation supernate of the lactobacillus reuteri is optimal. And the thallus components and viable bacteria have obvious effects in promoting the expression of anti-inflammatory factors in skin tissues. Therefore, the lactobacillus reuteri has a huge application prospect in preparation of a product for promoting synthesis of the natural active ingredient ceramide of the skin.

This invention belongs to the technical field of Mongolian medicine composition, and discloses a Mongolian medicine composition for treating osteoporosis, its preparation and application. The composition, by weight, consists of 5-15 parts of ginseng, 10-20 parts of dragon bone, 8-18 parts of gypsum, 6-16 parts of pomegranate, 3-9 parts of cardamom, 4-12 parts of safflower, 2-8 parts of cinnamon, and 2-8 parts of long pepper. This Mongolian medicine composition integrates characteristic Mongolian medicines such as ginseng and gypsum, following the Mongolian medicine theory of "harmonizing cold and heat, and combining tonification and purgation." It can simultaneously act on three key pathological links: "inhibiting osteoclast activity," "promoting osteogenic differentiation," and "regulating the inflammatory microenvironment of bone tissue," achieving multi-target synergistic treatment. It not only effectively improves low bone mass but also significantly relieves bone pain, fundamentally intervening in bone metabolic imbalance and achieving a comprehensive therapeutic effect that addresses both the symptoms and the root cause.

This invention discloses the application of induced pluripotent stem cell (EPC) derived from induced pluripotent stem cell differentiation in the preparation of stroke therapeutic agents. Through intravenous injection of EPCs into an animal model of stroke, this invention demonstrates that this method can treat stroke by inhibiting atherosclerosis, reducing cerebral infarction levels, promoting angiogenesis in lesioned brain tissue, improving inflammatory responses in lesioned brain tissue, and repairing nerve damage and brain injury. The above research results of this invention provide a new treatment method for stroke in clinical practice.

This invention belongs to the field of biomedical technology, specifically disclosing the application of cimicifuga in the preparation of drugs for treating periodontitis. Specifically, it relates to the application of cimicifuga in the preparation of drugs for treating periodontitis; and the application of cimicifuga in the preparation of drugs for treating alveolar bone defects (periodontal bone defects) caused by periodontitis. It also relates to the application of cimicifuga in the preparation of products for inhibiting macrophage polarization towards M1 and / or promoting macrophage polarization towards M2 in a single macrophage system. In this disclosure, cimicifuga has no significant toxicity to macrophages and has high safety; it targets and regulates macrophage polarization, inhibiting periodontal inflammation at its source; it significantly reduces inflammatory infiltration and osteoclast formation in periodontal tissues, effectively alleviating alveolar bone defects; and it provides a novel targeted immunotherapy drug for periodontitis, expanding the clinical application of single traditional Chinese medicine monomers.

The invention discloses application of a known compound, namely a thiazole carboxamide derivative (with the CAS number of 933886-42-1), in preparation of a medicine for treating acute lung injury / acute respiratory distress syndrome, the compound is an SLC39A1 agonist, zinc ions entering cells can be effectively increased, and by reducing the expression quantity of lung tissue inflammation genes IL-1beta and TNF-alpha of mice, the lung tissue inflammation genes IL-1beta and TNF-alpha can be effectively inhibited, so that the acute lung injury / acute respiratory distress syndrome can be effectively inhibited, and the acute lung injury / acute respiratory distress syndrome can be effectively inhibited. Therefore, lung cell infiltration in ALI / ARDS mice is reduced, oxidative damage and tissue damage of lung tissue, inflammatory factor expression and cell connection are improved, and a new choice is provided for treatment of ALI / ARDS.

The invention discloses application of eucommia polysaccharide obtained by an ultrasonic-assisted hot extraction method in preparation of a product for relieving food allergy. Specifically, the application of the eucommia polysaccharide in preparation of a medicine for relieving tissue inflammation caused by food allergy, the application of the eucommia polysaccharide in preparation of a medicine for relieving intestinal tract tissue damage caused by food allergy and the application of the eucommia polysaccharide in preparation of a medicine for relieving food allergy by adjusting the structure and function of intestinal flora. The eucommia polysaccharide obtained through extraction and purification is applied to an OVA-induced mouse allergy model, a control group, an OVA sensitization group and a polysaccharide intervention group are set, and allergy symptom scores, tissue pathological changes and intestinal flora changes are evaluated. Researches prove that the eucommia polysaccharide has the effect of relieving food allergy and can be applied to preparation of products for relieving food allergy. Therefore, the invention provides a scientific basis for comprehensive utilization of eucommia ulmoides leaf resources in relieving food anaphylaxis.

The invention discloses application of AKK bacteria in improving immunity and preparing products for preventing, treating and / or assisting in treating rhinitis, and belongs to the technical field of microorganisms. In order to solve the technical problems that in the prior art, treatment means for rhinitis cannot relieve symptoms for a long time, the single anti-inflammatory effect is limited, side effects are likely to be caused and the like, the invention provides a new Ackermann mucophila strain AKK IMMU, the AKK IMMU is preserved in Guangdong Microbial Culture Collection Center on November 3, 2025, the preservation number is GDMCC No: 67192, and the AKK IMMU is preserved in the Guangdong Microbial Culture Collection Center on November 2025. The strain can remarkably improve rhinitis model mouse nasal mucosa pathological damage, regulate serum oxidative stress indexes and regulate lung tissue inflammatory factors.

The invention relates to the technical field of biological medicines, and particularly discloses application of brucea javanica oil in preparation of a medicine for inhibiting radiation pneumonitis or idiopathic pulmonary fibrosis. When the brucea javanica oil is used for preparing the medicine for inhibiting radiation pneumonitis, the symptom of radiation pneumonitis can be remarkably relieved, the curative effect of the medicine is equivalent to that of dexamethasone, release of proinflammatory factors can be effectively inhibited, and inflammatory cascade reaction is blocked and lung tissue injury is relieved by down-regulating mRNA and protein expression of an HMGB1 / TLR4 / NF-kappa BP65 axis. The brucea javanica oil is applied to preparation of the medicine for treating idiopathic pulmonary fibrosis, lung tissue inflammatory cell infiltration can be effectively inhibited, abnormal collagen deposition can be reduced, expression of fibrosis promoting proteins COL1A1, VIM and ACTA2 can be down-regulated, and the pulmonary fibrosis process can be relieved by inhibiting fibroblast activation and extracellular matrix excessive deposition.

The invention relates to the field of fungal polysaccharide application, and discloses a preparation method and application of morchella polysaccharide. The preparation method comprises the following steps: step 1) leaching dry morchella esculenta powder with water to obtain a leaching solution; carrying out alcohol precipitation on the leach liquor to obtain a precipitate; 2) adding water into the precipitate for redissolving, removing protein, and then dialyzing and freeze-drying to obtain a morchella esculenta crude polysaccharide extract; 3, the morchella esculenta crude polysaccharide extract is dissolved in water and purified through adsorption chromatography, and the morchella esculenta polysaccharide is obtained.The morchella esculenta polysaccharide has the protection effect on alcoholic stomach injury in vivo and in vitro, stomach tissue inflammatory response is adjusted by adjusting an NF-kb channel, and reference value is provided for development application of the morchella esculenta polysaccharide.

The invention discloses application of miR-29a-3p in targeting PLSCR4 and inhibiting vascular inflammation and an evaluation method of miR-29a-3p, and relates to the technical field of biomedicine.The method comprises the following steps that miR-29a-3p simulant or inhibitor is transfected to human umbilical vein endothelial cells and then stimulated with TNF-alpha, inflammatory response is evaluated through qRT-PCR, Western blot, immunofluorescence, Transwell migration, mononuclear cell chemotaxis and scanning electron microscope technologies, and therefore the inflammatory response is evaluated. According to the present invention, the PLSCR4 is identified as the miR-29a-3p direct target through the dual luciferase reporter gene experiment, the overexpression or knockout effect of the PLSCR4 is evaluated through Annexin V-PI dyeing and flow cytometry, the in vivo model of the mouse is established, the intravenous injection of the miR-29a-3p agonist is performed, and the lung tissue inflammation is analyzed by using the immunohistochemical method; the invention discloses that miR-29a-3p inhibits the activation of NLRP3 inflammasomes by down-regulating PLSCR4, so that the CASP1 mediated GSDMD cutting and subsequent cell pyroptosis pore formation are inhibited.

The present invention relates to the use of Mucor racemosus and a metabolite thereof in the preparation of a drug for preventing and / or treating ulcerative colitis, which belongs to the technical field of biopharmaceuticals. Mucor racemosus CGMCC NO: 40320 and the metabolite 5mc (5-methylcytosine) thereof of the present disclosure can significantly mitigate problems of disease index, body weight loss and reduction in index of immune-related organs (e.g., spleen) in mice with ulcerative colitis disease, can alleviate the occurrence of inflammation in colon tissue, thereby improving the intestinal wall integrity of intestinal tissues, and thus can be used in the preparation of a drug for preventing and / or treating ulcerative colitis. The present disclosure expands the application fields of Mucor racemosus and provides guidance for clinical application of Mucor racemosus in the treatment of colitis.

The invention relates to application of a qi-regulating and blood-activating preparation in a medicine for preventing or treating altitude stress, and belongs to the technical field of medicine application. The qi-regulating and blood-activating preparation is prepared by extracting and processing fructus cinnamoii, borneol, ligusticum wallichii and allium macrostemon. Experimental research shows that the qi-regulating and blood-activating preparation can effectively improve plateau hypoxia athletic ability and heart functions, can effectively improve plateau hypoxia lung tissue inflammation infiltration, reduces alveolar wall thickness, reduces lung tissue fibrosis, and reduces myocardial cell LDH release, thereby achieving the effect of effectively preventing and treating acute altitude stress.

The application discloses a kind of gingival tissue hemodynamics spectral index construction systems based on near infrared spectroscopy, it is characterized in that, including visible near infrared spectrometer and data processing unit;Wherein, the visible near infrared spectrometer is used to collect the spectral data of each target site around the tooth to be detected;The data processing unit is used to normalize the spectral curve in each spectral data collected to consistent measurement background, determine the spectral absorption characteristics of gingival tissue oxyhemoglobin and deoxyhemoglobin is extracted;Then based on the spectral absorption characteristics obtained, gingival tissue hemodynamics index is calculated.The gingival tissue hemodynamics spectral index obtained based on the application can assist in quickly, accurately, non-invasively and cost-effectively completing periodontal tissue inflammation detection, and provides accurate and effective assistance for the clinical diagnosis of periodontitis.